NuShores Biosciences

Executive Summary

NuShores Biosciences is a private, preclinical-stage biotechnology company based in Nashville, TN, focused on advancing its proprietary NuCress™ scaffold platform for bone and tissue regeneration. The platform addresses large segmental bone defects, a significant unmet need in orthopedics and trauma surgery. Originating from over a decade of research at the University of Arkansas at Little Rock, the technology leverages patented biomaterials to promote natural bone healing. The company targets a market with limited effective solutions for critical-sized bone defects, where current standards of care—such as autografts and allografts—face constraints in availability, morbidity, and scalability. NuShores' approach aims to provide a synthetic, off-the-shelf alternative that could improve patient outcomes and reduce healthcare costs. As a preclinical entity, NuShores is actively advancing its lead candidate toward IND-enabling studies. The company's immediate priorities include completing in vivo efficacy and safety studies, scaling up manufacturing processes, and engaging with regulators. Success in these milestones could unlock significant value, particularly if the platform demonstrates superiority over existing bone graft substitutes. The company remains privately funded and has not disclosed total capital raised, but its focus on a validated technology and a large addressable market positions it as an attractive target for strategic partnerships or further investment. Near-term catalysts—including IND submission and preclinical data releases—will be critical de-risking events for the company as it transitions toward first-in-human trials.

Upcoming Catalysts (preview)

• Q4 2026IND Submission60% success
• Q3 2026Preclinical In Vivo Data Readout70% success
• H1 2027Strategic Partnership or Series A/B Funding40% success